Compare ELTK & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELTK | CTSO |
|---|---|---|
| Founded | 1970 | 1997 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.3M | 45.9M |
| IPO Year | 1997 | N/A |
| Metric | ELTK | CTSO |
|---|---|---|
| Price | $9.20 | $0.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $5.38 |
| AVG Volume (30 Days) | 5.7K | ★ 107.5K |
| Earning Date | 03-10-2026 | 03-11-2026 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $49,310,000.00 | $36,979,520.00 |
| Revenue This Year | $18.60 | $7.95 |
| Revenue Next Year | $9.04 | $8.80 |
| P/E Ratio | $54.51 | ★ N/A |
| Revenue Growth | 2.54 | ★ 23.89 |
| 52 Week Low | $7.65 | $0.60 |
| 52 Week High | $12.19 | $1.61 |
| Indicator | ELTK | CTSO |
|---|---|---|
| Relative Strength Index (RSI) | 54.03 | 52.02 |
| Support Level | $8.64 | $0.67 |
| Resistance Level | $9.41 | $0.74 |
| Average True Range (ATR) | 0.24 | 0.04 |
| MACD | 0.11 | 0.01 |
| Stochastic Oscillator | 64.06 | 71.61 |
Eltek Ltd is engaged in the technology business sector that manufactures and supplies technologically new custom-made circuitry solutions. It manufactures, markets, and sells custom-made printed circuit boards (PCBs), including high-density interconnect, flex-rigid and multi-layered boards. The Company markets its products mainly to the medical technology, defense and aerospace, industrial, telecom, and networking equipment industries. Its geographic areas are Israel, North America, the Netherlands, India, and Others. It generates the majority of its revenue from Israel.
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.